Oakworth Capital’s Takeda Pharmaceutical TAK Stock Holding History

Oakworth Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-114	Closed	-$1.7K	–	703
2025 Q1	$1.7K	Buy	+114	New	+$1.6K	﹤0.01%	634
2023 Q2	–	Sell	-745	Closed	-$12.3K	–	650
2023 Q1	$12.3K	Hold	745	–	–	﹤0.01%	417
2022 Q4	$11.6K	Hold	745	–	–	﹤0.01%	406
2022 Q3	$10K	Hold	745	–	–	﹤0.01%	457
2022 Q2	$10K	Hold	745	–	–	﹤0.01%	448
2022 Q1	$11K	Hold	745	–	–	﹤0.01%	445
2021 Q4	$10K	Hold	745	–	–	﹤0.01%	482
2021 Q3	$12K	Hold	745	–	–	﹤0.01%	463
2021 Q2	$13K	Sell	745 -12,303	-94%	-$209K	﹤0.01%	453
2021 Q1	$238K	Hold	13,048	–	–	0.03%	158
2020 Q4	$237K	Hold	13,048	–	–	0.03%	149
2020 Q3	$233K	Hold	13,048	–	–	0.04%	134
2020 Q2	$234K	Hold	13,048	–	–	0.04%	130
2020 Q1	$198K	Hold	13,048	–	–	0.05%	133
2019 Q4	$256K	Sell	13,048 -1,565	-11%	-$29.9K	0.04%	139
2019 Q3	$251K	Hold	14,613	–	–	0.05%	132
2019 Q2	$259K	Hold	14,613	–	–	0.05%	143
2019 Q1	$298K	Buy	+14,613	New	+$294K	0.06%	127

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Oakworth Capital's TAK Position: Q2 2025 in Review

Oakworth Capital sold out of Takeda Pharmaceutical (TAK) in Q2 2025, closing a stake of 114 shares — an estimated $1.7K sold.

Oakworth Capital first reported a position in TAK in Q1 2019 and held it in 18 quarters. The position peaked at $298K in Q1 2019. 315 funds tracked by Wall St. Rank hold TAK as of Q2 2025.

Oakworth Capital reported no remaining Takeda Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Oakworth Capital sold 114 Takeda Pharmaceutical shares in Q2 2025, an estimated $1.7K.
Oakworth Capital first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 18 quarters.
Oakworth Capital's Takeda Pharmaceutical position peaked at $298K in Q1 2019.
315 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2025.

Based on Oakworth Capital's 13F filing for Q2 2025, filed 17 Jul 2025.